Viking Therapeutics (NASDAQ:VKTX) Earns Buy Rating from HC Wainwright

Viking Therapeutics (NASDAQ:VKTX – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They currently have a $90.00 target price on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 6.26% from the stock’s previous close. […]

Related Keywords

Switzerland ,Swiss ,William Blair ,Greg Zante ,Maxim Group ,Dimensional Fund Advisors ,Blackrock Inc ,Securities Exchange Commission ,York Mellon Corp ,Therapeutics Inc ,Jpmorgan Chase Co ,Swiss National Bank ,Jefferies Financial Group ,Viking Therapeutics ,Get Free Report ,Financial Group ,Exchange Commission ,National Bank ,New York Mellon Corp ,Fund Advisors ,Viking Therapeutics Daily ,